Girard Partners’s AstraZeneca AZN Stock Holding History

Girard Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-170	Closed	-$13K	–	288
2018 Q3	$13K	Buy	+170	New	+$12.9K	﹤0.01%	672

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Girard Partners's AZN Position: Q4 2018 in Review

Girard Partners sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 170 shares — an estimated $13K sold.

Girard Partners first reported a position in AZN in Q3 2018 and held it in 1 quarter. The position peaked at $13K in Q3 2018. 556 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

Girard Partners reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 170 AstraZeneca shares in Q4 2018, an estimated $13K.
Girard Partners first reported a position in AstraZeneca in Q3 2018 and held it in 1 quarter.
Girard Partners's AstraZeneca position peaked at $13K in Q3 2018.
556 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.